Qure.ai is partnering with Microsoft to integrate its AI-driven lung cancer detection and management suite into Microsoft’s Precision Imaging Network, dramatically expanding the reach of its diagnostic tools in U.S. hospitals.
Glimpse:
Qure.ai’s comprehensive lung cancer AI suite built using large language models (LLMs) and agentic AI will be deployed via Microsoft’s cloud-based Precision Imaging Network. This will enable hospitals across the U.S. to access tools for early nodule detection on chest X-rays, CT-based quantification, and patient-care coordination, helping accelerate diagnosis, improve outcomes, and lower costs.
Qure.ai has announced a strategic collaboration with Microsoft to integrate its end-to-end lung cancer detection, measurement, and management AI suite into Microsoft’s Precision Imaging Network. The move is aimed at scaling Qure.ai’s diagnostic solutions across U.S. health systems, leveraging Microsoft’s cloud infrastructure and imaging platform to simplify adoption and deployment.
The Qure.ai lung cancer suite uses advanced AI techniques including large language models and agentic AI, and is designed to augment workflows between radiologists, pulmonologists, interventionalists, and thoracic surgery teams. Key tools in the suite include qXR-LN for incidental nodule detection on chest X-rays, qCT-LN Quant for volumetric measurement and tracking on CT scans, and qTrack for patient-management coordination.
Jim Mercadante, Chief Commercial Officer at Qure.ai, highlighted that the partnership will bring “new levels of choice and simplicity” to hospitals across the U.S., enabling faster triage and monitoring, and improving overall care delivery. Microsoft’s Peter Durlach, Corporate VP and Chief Strategy Officer for Health & Life Sciences, noted that the integration will unlock efficiencies from early detection to multidisciplinary coordination and advance Microsoft’s mission to democratize AI-powered care. Qure.ai already has a global footprint, operating in over 105 countries across more than 4,800 sites. Many of its lung cancer algorithms are FDA-cleared, enabling deployment either as standalone products or as a unified clinical workflow. This collaboration with Microsoft represents a major step forward in democratizing access to AI-driven oncology diagnostics in the U.S.
“The Qure.ai and Microsoft collaboration brings new levels of choice and simplicity for hospitals and health systems across the USA It will power-up access to early detection, triage and tracking to improve patient care, boost survival rates and reduce overall healthcare costs.”
By
HB Team
